Texting to beat HIV: simple phone messages could help women stay healthy
NCT ID NCT06745050
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether personalized text messages can help HIV-positive women in Africa who sell sex take their antiretroviral therapy (ART) regularly. 350 women will either get standard care or standard care plus text reminders and tips for six months. The goal is to see if more women in the text-message group achieve an undetectable viral load, meaning the virus is well controlled.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- text message support program
- What this could lead to
- If it works, this could offer a simple, low-cost way to help HIV+ women stick with their medication and keep the virus under control.
- What could go wrong
- This is a behavioral intervention, not a new drug. Success depends on whether text messages alone can change long-term habits, and results may not apply to other groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 350 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Age \>18 * Transactional sex in past 12 months * HIV-positive * Not currently on ART * Enrolled in one of the Sex Workers Outreach Program clinics * Has access to mobile phone * Willing to receive study text messages * Able to read or have someone else read Exclusion Criteria: * Plans to move away in next 6 months * Undetectable viral load at baseline * Pregnant
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV antiretroviral therapy (ART) adherence are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Partner for Health and Development in Africa
RECRUITINGNairobi, Kenya
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can remote counseling help people with HIV cut back on alcohol?
- Can a Once-Daily HIV pill with food match Twice-Daily dosing during TB treatment?
- Four weeks vs twelve weeks: can a shorter TB prevention course work?
- Can a phone app keep young people with HIV engaged in care?
- Massive Real-World database aims to map how chronic diseases interact
- How do HIV drugs behave when kidneys fail? study measures blood levels